Company Profile Senior Management Team Board of Directors Scientific Advisory Board Vision

Overview Protein Misfolding & Disease Pharmacological Chaperones Proposed Mechanism of Action

Pipeline Fabry – AT1001 Gaucher – AT2101 Pompe – AT2220 Ongoing Clinical Trials

Senior Management Team Corporate Governance Press Releases Events & Presentations SEC Filings Stock Performance Investor FAQs Contact Us

Overview Career Opportunities Benefits Working at Amicus

Investors:
John Quirk
Porter Novelli Life Sciences
(212) 601-8296

Media:
Cory Tromblee
Porter Novelli Life Sciences
(617) 897-8294

Related Articles

Summer 2005	Newsweek Special Edition: "A Fix for Faulty Proteins" (pdf)